The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Kolb, H., Schattenberg, A., Goldman, J., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., & Niederwieser, D. (1995) · Blood · doi:10.1182/blood.v86.5.2041.bloodjournal8652041 · Cited by 1,934
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Gong, J.-H., Maki, G., & Klingemann, H.-G. (1994) · PubMed · Cited by 723
Self-citationCooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Parkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1347 · Cited by 475
Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 469
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
Self-citationCD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
Dazzi, F., Szydlo, R. M., Craddock, C., Cross, N. C. P., Kaeda, J., Chase, A., Olavarria, E., van Rhee, F., Kanfer, E., Apperley, J. F., et al. (2000) · Blood · doi:10.1182/blood.v95.1.67 · Cited by 290
Serial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic Antibodies
Bhat, R., & Watzl, C. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000326 · Cited by 286
Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92
Tonn, T., Becker, S., Esser, R., Schwabe, D., & Seifried, E. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/15258160152509145 · Cited by 267
Self-citationUherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Self-citationFactors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92
Maki, G., Klingemann, H.-G., Martinson, J. A., & Tam, Y. K. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/152581601750288975 · Cited by 262
Self-citationMüller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Self-citationTam, Y. K., Maki, G., Miyagawa, B., Hennemann, B., Tonn, T., & Klingemann, H.-G. (1999) · Human Gene Therapy · doi:10.1089/10430349950018030 · Cited by 203
Self-citationEsser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
Self-citationSahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Binyamin, L., Alpaugh, R. K., Hughes, T. L., Lutz, C. T., Campbell, K. S., & Weiner, L. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6392 · Cited by 176
Antileukemia activity of a natural killer cell line against human leukemias.
Yan, Y., Steinherz, P. G., Klingemann, H., Dennig, D., Childs, B. H., McGuirk, J. P., & O’Reilly, R. J. (1998) · PubMed · Cited by 167
Self-citationDaldrup-Link, H. E., Meier, R., Rudelius, M., Piontek, G., Piert, M., Metz, S., Settles, M., Uherek, C., Wels, W., Schlegel, J., et al. (2005) · European Radiology · doi:10.1007/s00330-004-2526-7 · Cited by 167
Boissel, L., Betancur, M., Wels, W. S., Tuncer, H., & Klingemann, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.024 · Cited by 166
Self-citationTarn, Y. K., Martinson, J., Doligosa, K., & Klingernann, H.-G. (2003) · Cytotherapy · doi:10.1080/14653240310001523 · Cited by 149
Tam, Y. K., Miyagawa, B., HO, V. C., & Klingemann, H.-G. (1999) · Journal of Hematotherapy · doi:10.1089/106161299320316 · Cited by 133
Self-citationEx vivo expansion of natural killer cells for clinical applications
Klingemann, H.-G., & Martinson, J. (2004) · Cytotherapy · doi:10.1080/14653240310004548 · Cited by 117
Self-citationMcKenna, D. H., Sumstad, D., Bostrom, N., Kadidlo, D. M., Fautsch, S. K., McNearney, S. A., DeWaard, R., McGlave, P. B., Weisdorf, D. J., Wagner, J. E., et al. (2007) · Transfusion · doi:10.1111/j.1537-2995.2006.01145.x · Cited by 117
Natural killer cells: a review of manufacturing and clinical utility
Koepsell, S. A., Miller, J. S., & McKenna, D. H. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03724.x · Cited by 88
Use of natural killer cells in hematopoetic stem cell transplantation
Passweg, J. R., Stern, M., Koehl, U., Uharek, L., & Tichelli, A. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704810 · Cited by 84
Self-citationPurification of human natural killer cells using a clinical-scale immunomagnetic method
Iyengar, R. V., Handgretinger, R., Babarin-Dorner, A., Leimig, T., Otto, M., Geiger, T. L., Holladay, M. S., Houston, J., & Leung, W. H. (2003) · Cytotherapy · doi:10.1080/14653240310003558 · Cited by 76
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
Tassev, D. V., Cheng, M., & Cheung, N. K. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.66 · Cited by 72
Klingemann, H., Grodman, C., Cutler, E., Duque, M., Kadidlo, D. M., Klein, A., Sprague, K. A., Miller, K. B., Comenzo, R., Kewalramani, T., et al. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03764.x · Cited by 46
Self-citationCellular therapy of cancer with natural killer cells—where do we stand?
Klingemann, H. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.03.011 · Cited by 37
Self-citation
Cited by
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R., Liu, E., & Shpall, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 453
Metadata
- Authors
- Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G.
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 15
- Issue
- 12
- Pages
- 1563-1570
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W2036088843
- Cited by
- 467
- References
- 38
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.